Our team of experts brings you cancer-related news and research updates.
Jill Chang says she always knew she might get cancer some day. It seemed to run in the family. But she never dreamed she’d be diagnosed with cancer at age 30.
For women with a certain genetic makeup, being overweight or obese significantly raises the risk for colorectal cancer, according to a recent study published in JNCI: Journal of the National Cancer Institute.
To help both the death and diagnosis rates of colorectal cancer drop—and to help those who develop it survive and thrive—the American Cancer Society (ACS) funds the research of scientists across the country who use the latest evidence and cutting-edge technology to help prevent and treat CRC. Here are two of their stories.
Here’s a look at some of the significant advances in cancer research from the past 10 years that are helping to save lives now – and how American Cancer Society staff and funded researchers have contributed to each one.
As of 2016, more than 200 targeted therapies (also called precision medicines) were available in the United States, and more than 2,000 were in the last stages of development—half of them to treat cancer. For many of these drugs, doctors first use genomic testing of the cancer cells to get an idea of whether the treatment will work. Yet, nearly 1 in 4 oncologists rarely or never mention costs when they talk about the need for genomic testing with their cancer patients, according to a new study led by American Cancer Society (ACS) investigators.
Most cancers are not caused by inherited gene mutations. But if cancer runs in your family, you may want to consider genetic testing options.
The US Food and Drug Administration (FDA) has approved Rozlytrek (entrectinib) for adults and adolescents with tumors that test positive for NTRK gene changes, which can help cancerous tumors grow.
We’ve known for a while that triple-negative breast cancer is more common in Black women in the United States, compared to other groups. The news is the prevalence varies significantly depending on where these women were born. American Cancer Society (ACS) researchers found that among Black women, those born in the US and Western Africa were diagnosed more often with triple-negative breast cancer than women born in East Africa. The authors published their findings in Cancer, an ACS peer-reviewed journal.